Allergy Therapeutics plc (LON:AGY) had its Corporate rating reiterated by FinnCap

Analyst Ratings For Allergy Therapeutics plc (LON:AGY)

Story continues below

Today, FinnCap reiterated its Corporate rating on Allergy Therapeutics plc (LON:AGY).

There are 3 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Allergy Therapeutics plc (LON:AGY) is Buy with a consensus target price of GBX 46 per share, a potential .

Some recent analyst ratings include

  • 9/27/2018-Allergy Therapeutics plc (LON:AGY) had its Corporate rating reiterated by FinnCap
  • 9/26/2018-Allergy Therapeutics plc (LON:AGY) had its Buy rating reiterated by Numis Securities with a GBX 45 price target
  • 9/28/2017-Allergy Therapeutics plc (LON:AGY) had its Buy rating reiterated by Panmure Gordon
  • 4/4/2017-Allergy Therapeutics plc (LON:AGY) had its Buy rating reiterated by Stifel Nicolaus with a GBX 60 price target


    About Allergy Therapeutics plc (LON:AGY)
    Allergy Therapeutics plc, a specialty pharmaceutical company, focuses on allergy vaccination primarily in Europe. The company's primary flagship product is the Pollinex Quattro for the treatment of allergic conditions. It offers monophosphoryl-lipid A, a substance that enhances the immune response to an antigen or allergen; sublingual product, including Oralvac Compact; Venomil product, which is used for the wasp and bee treatment; and synbiotics that are special formulations of prebiotics and probiotics, such as Kallergen-Th, ATI Prob, and Pollagen. The company also provides Acarovac Plus, a novel microcrystalline tyrosine adsorbed, modified-allergen product developed for treatment of perennial mite allergy; and DAP, a product for use in the diagnosis of type I or immediate hypersensitivity to benzyl penicillin and related antibiotics (beta lactams) by means of cutaneous tests (prick and intradermal). In addition, it develops products based on synbiotics that are Kallergen Th and SynGut; Acarovac Plus and Acarovac MPL that are next generation products for dust mite immunotherapy; Polyvac, a peanut vaccine; and G204, G205, and G306, as well as PQBirch 301 and PQBirch 204 that are subcutaneous immunotherapies, which are in various development phases. The company markets its products in injectable and sublingual formats under various brands. Allergy Therapeutics plc was founded in 1934 and is based in Worthing, the United Kingdom.

    Recent Trading Activity for Allergy Therapeutics plc (LON:AGY)
    Shares of Allergy Therapeutics plc closed the previous trading session at 24.25 0.00 0.00% with shares trading hands.

    An ad to help with our costs